hero image

Finally, kidney disease meets a true opponent

We’re pioneering precision-based medicines to revolutionize the treatment of kidney diseases.

A global epidemic with an innovation gap

Chronic kidney disease (CKD) affects 780 million people globally–that’s one in every ten people. Progression to end-stage kidney disease is common, and severely impacts quality of life. Despite this, fewer than 1% of all research programs across the biopharmaceutical industry are focused on reducing the substantial burden of CKD.

Learn more about the problem we aim to solve

People worldwide with CKD


People die annually from kidney disease worldwide


Of all active pipeline programs in the biopharmaceutical industry are for kidney diseases

Our Precision Medicine Approach to Treat Kidney Disease

We are applying precision medicine to discover, develop and commercialize disease-modifying kidney disease treatments. We believe our approach enables us to uncover subsets of patients based on genetic and environmental factors within heterogenous kidney diseases.

We have a robust pipeline of novel, precision medicine product candidates targeting kidney diseases with significant unmet medical needs. Our lead program, GFB-887, is designed to treat people with focal segmental glomerulosclerosis (FSGS) caused by an overactivation of the TRPC5-Rac1 pathway.

Explore Our Pipeline
Scientist in Lab

Our Precision Medicine Product Engine: Integrating Kidney Genetics & Biology

Our product engine allows us to discover, validate and drug novel targets while identifying patient subsets most likely to respond to our treatments.

Learn about our foundational product engine

A bold mission to transform the lives of people living with kidney disease

Our Mission

To deliver disease-modifying precision medicines that bring hope and renewed quality of life to people living with kidney diseases.

Our Vision

We aspire to save kidneys and end dialysis.

The Feeder Interview Series

Check out our new interview series, The Feeder. We’re speaking with people impacted by kidney disease, and a wide range of experts who are driving change, innovation and hope in the kidney space.

Check Out The Latest Episodes
Goldfinch Bio Expands Board of Directors with Appointments of Meryl Zausner, Hon. William “Mo” Cowan and Tyrell Rivers, Ph.D.
Read More
Goldfinch Bio Announces Appointment of Robin A. Walker, J.D., as Chief Legal Officer
Read More
Goldfinch Bio Presents Clinical Data from Phase 1 Trial Supporting Advancement of GFB-887 as a Precision Medicine for Patients with Kidney Diseases
Read More

In 2020 we were named one of the most promising companies in the biotechnology industry by FierceBiotech.

Become a Finch

Join Us!

We aspire to be the world’s leading precision medicine kidney company – dedicated to our mission, focused on pursuing world-class science and fully committed to improving the lives of people with kidney disease.